News Center

Ambrx Appoints Gary Yeung as Chief Financial Officer and Chief Operating Officer

1月 7, 2021 | 未分类
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive...

FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer

1月 4, 2021 | 未分类
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or...

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

12月 10, 2020 | 未分类
• 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU • Multiple Global Phase...

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics

11月 9, 2020 | 未分类
SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed...

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

1月 13, 2020 | 未分类
Sino Biopharma receives exclusive rights to develop and commercialize two Ambrx enabled drug products in China Ambrx receives upfront payment plus undisclosed milestone payments and royalties. SAN DIEGO, USA and BEIJING,...